
Ice Cream Recall In 23 States After Possible Listeria Contamination
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
Millions of ice cream bars distributed in schools and businesses across 23 states have been recalled amid possible listeria contamination, with the U.S. Food and Drug Administration (FDA) warning of "adverse health consequences" should someone consume the affected product.
Why It Matters
Rich's Ice Cream products are available in schools and businesses in 23 states. On its website, the Florida-based ice cream company says it only ships "to large wholesale ice cream distributors all over the US."
"These distributors then sell our ice cream to schools and businesses in their local market," the website said.
Newsweek reached out to Rich's Ice Cream by email for comment outside of normal business hours on Monday.
What to Know
Numerous flavors of Rich's Ice Cream have been pulled from store shelves amid possible listeria contamination. In total, 110,292 cases of ice cream were recalled, with 96 units in each case resulting in more than 10 million bars of ice cream impacted. Lot numbers 24351 through 25156 were included in the recall.
A stock photo of an ice cream bar.
A stock photo of an ice cream bar.
bombermoon/Getty
The ice cream was distributed to 23 states, including California, Pennsylvania, Ohio, Georgia, New York, New Jersey, Florida, Texas, Virginia, Arizona, Alabama, Illinois, Missouri, Massachusetts, Tennessee, Iowa, South Carolina, Oregon, Oklahoma, Nevada, Louisiana, Wisconsin, and Nebraska, as well as Nassau and the Bahamas.
Listeriosis is a bacterial infection that can occur after consuming food contaminated by the Listeria monocytogenes bacteria. Symptoms can range from mild to life-threatening, according to a report by the Cleveland Clinic, and are particularly dangerous for those who are pregnant or who have a weakened immune system.
Foods that can be contaminated by Listeria include hot dogs, deli meats, and soft cheese. Symptoms can include fever, headache, chills, fatigue, vomiting and diarrhea. It can take as long as two weeks for symptoms to appear after consuming a contaminated product, the Cleveland Clinic reported.
When was the recall issued?
Rich's Ice Cream voluntarily issued the recall on June 27, according to the FDA report. On July 17, the FDA classified the recall as a Class II, meaning that exposure to the product could cause "adverse health consequences."
Which products were recalled? Full List
Products affected by the recall include the following varieties:
Chocolate Crunch Cake Bar
Strawberry Shortcake Bar
Rich Bar
Crumbled Cookie Bar
Orange Cream Bar
Fudge Frenzy Bar
Cotton Candy Twirl Bar
Savagely Sour BlueRaspberry Bar
Savagely Sour Cherry Bar
Cool Watermelon Bar
What People Are Saying
The FDA, in an online definition, about Class II recalls: "A situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote."
Rich's Ice Cream on its webpage: "Our products are available in schools and on street vending trucks (a.k.a. "the ice cream man") all across the country."
What Happens Next
The recall is listed as ongoing, according to the FDA. Instructions on how to contact the company or if refunds would be offered were not included in the recall.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Bloomberg
27 minutes ago
- Bloomberg
FDA Rejects Replimune's Skin Cancer Treatment, Shares Sink
US regulators rejected a skin cancer treatment from Replimune Group Inc. in another sign of the agency's new leadership taking a hard line on drug approvals. The US Food and Drug Administration denied the company's application to treat advanced melanoma with a combination of its immunotherapy and another cancer drug.
Yahoo
an hour ago
- Yahoo
Kaida BioPharma Participates in the Virtual Investor 'What's Your Story' Summer Spotlight On-Demand Conference
– Video webcast now available on-demand FORT LAUDERDALE, FL, July 22, 2025 (GLOBE NEWSWIRE) -- Kaida BioPharma ('Kaida' or the 'Company'), an early-stage pharma company dedicated to advancing targeted anti-cancer therapies to address hormone-driven cancers affecting women, today announced Stella Vnook, PhD, Co-Founder of Kaida, participated in the Virtual Investor 'What's Your Story' Summer Spotlight On-Demand Conference. For the event, Dr. Vnook dove deeper into her dedication to the Company, how she got to where she is today and provided insight into why she is so passionate about the Company's program in development. The on-demand video webcast is now available on About Kaida BioPharmaKaida BioPharma was founded on the research principles and clinical evidence of the therapeutic benefit of blocking the binding of prolactin (PRL), a multifunctional hormone, to its receptor (PRLR), given their roles as growth factors in tumor growth and proliferation. The Company's lead product candidate KAD101 is a growth hormone antagonist designed to selective and effectively block the tumoral PRL/PRLR axis which has been shown to induce programmed cell death (autophagy) in gynecologic tumors. The Company is collaborating closely with Dr. John Langenheim, professor at Thomas Jefferson University, and Dr. Anil Sood, professor and vice chair for translational research in the departments of gynecologic oncology and cancer biology at MD Anderson Cancer Center, who have both published extensive research on prolactin and its role as a growth factor in tumor growth and progression and the potential therapeutic benefit of KAD101. Kaida is dedicated to providing a new hope for patients with treatment-resistant gynecological cancers. The Company's mission is to develop innovative therapies that target the specific needs of those patients, offering a medical treatment that can make a significant difference. For more information, please visit ContactJenene ThomasChief Executive OfficerJTC Team, LLCT: 908.824.0775E: kaida@ Sign in to access your portfolio

Yahoo
an hour ago
- Yahoo
IQVIA beats quarterly estimates on resilient demand for healthcare analytics
(Reuters) -Contract research firm IQVIA Holdings posted second-quarter profit and revenue above Wall Street expectations on Tuesday, as demand rose for its healthcare data and analytics services, sending shares up around 8% in premarket trading. IQVIA's technology and analytics unit, which serves pharmaceutical and consumer health companies, benefited from higher drug approvals by the U.S. Food and Drug Administration. Still, the company narrowed its annual earnings forecast as drugmakers and biotech companies have been cancelling orders given to contract research firms, in response to the U.S. government's drug price negotiation program, proposed federal research budget cuts and potential tariffs. The Trump administration has been considering separate tariffs for the pharmaceutical industry, which could be as high as 200%. But analysts said that, overall, the quarterly results had "more pluses than minuses." "All-in, this print could have been worse and should clear a fairly low bar heading into the quarter," Leerink Partners analyst Michael Cherny said in a note. Quarterly sales at the technology and analytics unit was $1.63 billion, compared with estimates of $1.60 billion, according to data compiled by LSEG. IQVIA's total quarterly revenue rose 5.3% to $4.02 billion, beating analysts' average estimate of $3.96 billion. On an adjusted basis, it reported profit of $2.81 per share for the quarter ending June 30, above expectations of $2.77 per share. IQVIA now expects annual adjusted profit per share between $11.75 and $12.05, compared with $11.70 to $12.10 earlier. The Durham, North Carolina-based company also narrowed its annual revenue expectations to between $16.1 billion and $16.3 billion, from $16 billion to $16.4 billion earlier. The new forecast assumes a roughly $100 million COVID-related impact. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data